

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Rule 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):  
January 6, 2020**

---

**CRH MEDICAL CORPORATION**  
(Exact name of registrant as specified in its charter)

---

**British Columbia, Canada**  
(State or other jurisdiction  
of incorporation)

**001-37542**  
(Commission  
File Number)

**Not Applicable**  
(IRS Employer  
Identification No.)

**Suite 578 - 999 Canada Place, World Trade Center, Vancouver,  
British Columbia, Canada**  
(Address of principal executive offices)

**V6C 3E1**  
(Zip Code)

**(604) 633-1440**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name of former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**ITEM 7.01****REGULATION FD DISCLOSURE**

On January 6, 2020, CRH Medical Corporation issued a press release regarding the appointment of Tom Sanders as Vice President of Commercial Development. A copy of the press release is being furnished herewith as Exhibit 99.1.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS****(d) Exhibits**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
<a href="#"><u>99.1</u></a>	<a href="#"><u>Press Release issued by CRH Medical Corporation on January 6, 2020</u></a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

***CRH MEDICAL CORPORATION***

---

(Registrant)

Date: January 6, 2020

By: /s/ Richard Bear

Name: Richard Bear

Title: Chief Financial Officer

# CRH Medical Appoints Tom Sanders as Vice President of Commercial Development

## *New Position Created to Accelerate Growth of CRH's O'Regan System*

VANCOUVER, Jan. 6, 2020 /CNW/ - **CRH Medical Corporation** (TSX: CRH) (NYSE MKT: CRHM) ("CRH" or the "Company"), today announced the appointment of Tom Sanders as Vice President of Commercial Development.

Mr. Sanders joins CRH with over 30 years of experience as both an executive and entrepreneur and will focus on identifying and implementing a range of strategies that will support the growth of the O'Regan System. O'Regan is a single-use, disposable, non-surgical hemorrhoid-banding technology that is safe and highly effective in treating all grades of hemorrhoids.

Mr. Sanders has extensive experience leading business development, strategic planning, commercial and operational activities. He joins CRH formerly from The GI Alliance, a Waud Capital Partners-sponsored gastrointestinal services organization that supports more than 315 independent gastroenterologists across five states, where he served as Senior Vice President of Business Development and Strategic Growth. Prior to joining GI Alliance, Mr. Sanders was founder, and Chief Executive Officer of Captify Health, which provided technology-enabled services for physician practices, health plans and health systems.

"On behalf of the Board of Directors and our senior leadership group, I am pleased to welcome Tom to the CRH team," said Dr. Tushar Ramani, Chief Executive Officer of CRH. "With his deep understanding of the healthcare industry and experience in the gastroenterology services market, Tom is exceptionally qualified to lead our O'Regan product segment. Moreover, Tom's arrival highlights the first time in our history that we have had an executive dedicated to leading, expanding and growing the CRH O'Regan segment."

"I am excited to join CRH at such an exciting stage in its development, with its rapidly expanding anesthesia services footprint and its clinically differentiated O'Regan product offering," commented Mr. Sanders. "With a market opportunity that we believe exceeds \$100 million, we expect to develop and execute a number of strategies to fully optimize O'Regan's growth."

### **About CRH Medical Corporation**

CRH Medical Corporation is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases. In 2014, CRH became a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures in ambulatory surgical centers. To date, CRH has completed 25 anesthesia acquisitions. CRH now serves 58 ambulatory surgical centers

in 11 states and performs approximately 374,000 procedures annually. In addition, CRH owns the CRH O'Regan System, a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. CRH distributes the O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves. The O'Regan System is currently used in all 48 lower US states.

View original content:<http://www.prnewswire.com/news-releases/crh-medical-appoints-tom-sanders-as-vice-president-of-commercial-development-300981907.html>

SOURCE CRH Medical Corporation

View original content:

<http://www.newswire.ca/en/releases/archive/January2020/06/c9898.html>

%CIK: 0001461119

**For further information:** Constantine Davides, CFA, 339-970-2846,  
[constantine.davides@westwicke.com](mailto:constantine.davides@westwicke.com)

CO: CRH Medical Corporation

CNW 14:00e 06-JAN-20